369 related articles for article (PubMed ID: 24567311)
1. Successful treatment of an infant infected with refractory C. parapsilosis with caspofungin.
Ozkaya-Parlakay A; Tezer H; Kazmacan T; Gulhan B; Unal S
J Trop Pediatr; 2014 Aug; 60(4):329-30. PubMed ID: 24567311
[TBL] [Abstract][Full Text] [Related]
2. Successful caspofungin treatment of multidrug resistant Candida parapsilosis septicaemia in an extremely low birth weight neonate.
Yalaz M; Akisu M; Hilmioglu S; Calkavur S; Cakmak B; Kultursay N
Mycoses; 2006 May; 49(3):242-5. PubMed ID: 16681818
[TBL] [Abstract][Full Text] [Related]
3. Caspofungin therapy of neonates with invasive candidiasis.
Odio CM; Araya R; Pinto LE; Castro CE; Vasquez S; Alfaro B; Sàenz A; Herrera ML; Walsh TJ
Pediatr Infect Dis J; 2004 Dec; 23(12):1093-7. PubMed ID: 15626944
[TBL] [Abstract][Full Text] [Related]
4. Caspofungin for refractory candidemia in neonates.
Manzar S; Kamat M; Pyati S
Pediatr Infect Dis J; 2006 Mar; 25(3):282-3. PubMed ID: 16511405
[No Abstract] [Full Text] [Related]
5. Successful treatment with caspofungin of refractory Candida krusei candidemia in a very low birth weight preterm infant.
Natale F; Castronovo A; Regoli D; De Curtis M; Manzoni P
Pediatr Infect Dis J; 2009 May; 28(5):452. PubMed ID: 19295457
[No Abstract] [Full Text] [Related]
6. Comparative in vitro susceptibility of clinical isolates of Candida paparsilosis complex and other Candida species to caspofungin and anidulafungin by Etest.
Khan Z; Ahmad S; Joseph L; Chandy R; Theyyathel A
J Chemother; 2011 Apr; 23(2):97-101. PubMed ID: 21571626
[TBL] [Abstract][Full Text] [Related]
7. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.
Pfaller MA; Diekema DJ; Andes D; Arendrup MC; Brown SD; Lockhart SR; Motyl M; Perlin DS;
Drug Resist Updat; 2011 Jun; 14(3):164-76. PubMed ID: 21353623
[TBL] [Abstract][Full Text] [Related]
8. Emergence of Candida tropicalis resistant to caspofungin.
Pasquale T; Tomada JR; Ghannoun M; Dipersio J; Bonilla H
J Antimicrob Chemother; 2008 Jan; 61(1):219. PubMed ID: 18024953
[No Abstract] [Full Text] [Related]
9. Prevalence rates and antifungal susceptibility profiles of the Candida parapsilosis species complex: results from a nationwide surveillance of candidaemia in Brazil.
Gonçalves SS; Amorim CS; Nucci M; Padovan AC; Briones MR; Melo AS; Colombo AL
Clin Microbiol Infect; 2010 Jul; 16(7):885-7. PubMed ID: 19686280
[TBL] [Abstract][Full Text] [Related]
10. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance.
Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2006 Mar; 44(3):760-3. PubMed ID: 16517851
[TBL] [Abstract][Full Text] [Related]
11. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage.
Forrest GN; Weekes E; Johnson JK
J Infect; 2008 Feb; 56(2):126-9. PubMed ID: 18082269
[TBL] [Abstract][Full Text] [Related]
12. Anidulafungin versus caspofungin in a mouse model of candidiasis caused by anidulafungin-susceptible Candida parapsilosis isolates with different degrees of caspofungin susceptibility.
Dimopoulou D; Hamilos G; Tzardi M; Lewis RE; Samonis G; Kontoyiannis DP
Antimicrob Agents Chemother; 2014; 58(1):229-36. PubMed ID: 24145540
[TBL] [Abstract][Full Text] [Related]
13. Neonatal liver abscesses due to Candida infection effectively treated with caspofungin.
Filippi L; Poggi C; Gozzini E; Meleleo R; Mirabile L; Fiorini P
Acta Paediatr; 2009 May; 98(5):906-9. PubMed ID: 19187395
[TBL] [Abstract][Full Text] [Related]
14. Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database.
Colombo AL; Ngai AL; Bourque M; Bradshaw SK; Strohmaier KM; Taylor AF; Lupinacci RJ; Kartsonis NA
Antimicrob Agents Chemother; 2010 May; 54(5):1864-71. PubMed ID: 20231388
[TBL] [Abstract][Full Text] [Related]
15. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis.
Spreghini E; Orlando F; Tavanti A; Senesi S; Giannini D; Manso E; Barchiesi F
J Antimicrob Chemother; 2012 Sep; 67(9):2195-202. PubMed ID: 22635526
[TBL] [Abstract][Full Text] [Related]
17. Effects of caspofungin against Candida guilliermondii and Candida parapsilosis.
Barchiesi F; Spreghini E; Tomassetti S; Della Vittoria A; Arzeni D; Manso E; Scalise G
Antimicrob Agents Chemother; 2006 Aug; 50(8):2719-27. PubMed ID: 16870764
[TBL] [Abstract][Full Text] [Related]
18. A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients.
Hsu DI; Nguyen M; Nguyen L; Law A; Wong-Beringer A
J Antimicrob Chemother; 2010 Aug; 65(8):1765-70. PubMed ID: 20554567
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of Candida albicans septicemia in a preterm infant with severe congenital ichthyosis (Harlequin baby).
Haase R; Kreft B; Foell J; Kekulé AS; Merkel N
Pediatr Dermatol; 2009; 26(5):575-8. PubMed ID: 19840314
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of caspofungin in invasive candidiasis and candidemia--de-escalation strategy.
Lichtenstern C; Nguyen TH; Schemmer P; Hoppe-Tichy T; Weigand MA
Mycoses; 2008; 51 Suppl 1():35-46. PubMed ID: 18471160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
